Unparalleled access to clinical data - one year on
Over 3,000 clinical documents published, 3,600 registered users and positive stakeholder feedback
One year ago today, the European Medicines Agency (EMA) became the first regulatory authority to give open access to clinical data submitted by companies in support of their marketing authorisation applications.
EMA’s flagship policy on the publication of clinical data enables citizens, including researchers and academics, to directly access the clinical reports underpinning the regulatory evaluation of a medicine’s clinical efficacy and safety via its clinical data publication (CDP) website. This facilitates the independent re-analysis of data after a medicine has been approved and enhances scientific knowledge. Increased transparency facilitates knowledge sharing, leading to more efficient medicine development programmes and ultimately benefitting innovation.
Patients and healthcare professionals can find out more about the data supporting the approval of medicines they are taking or prescribing.
In a recent survey of web users to evaluate implementation of the policy, three quarters of responders agree that the proactive publication of clinical data helps EMA to build public trust and confidence in its scientific and decision-making processes. Two thirds of responders agree that the data made available helps researchers to re-assess the clinical data.
As of 20 October 2017, clinical reports on 50 medicines, including orphan, biosimilar and generic medicines, as well as medicines for use in children, are publicly available on the CDP website. This amounts to 3,279 clinical documents, totalling more than 1.3 million pages. The majority of the data relates to the approval of new medicines, but there is also data for medicines that are already authorised and for which an extension of their clinical use has been sought.
Published data have attracted a total of 3,641 users, resulting in 22,164 document views and 80,537 document downloads for non-commercial research purposes.
EMA provides detailed guidance and hosts regular webinars with industry stakeholders to facilitate the publication process for these data.
62% of responders in EMA’s survey say that the data are useful and 87% say the data are presented in an understandable format, despite the redaction or anonymisation of certain information in line with European legislation on personal data protection. Participants in the survey included researchers, healthcare professionals, patients and industry.
EMA’s initiative has shaped the global debate towards more transparency and benefits academic research and the practice of medicine as a whole.
-  The survey was web-based, voluntary and available for three months. Full results will be published in due course.
-  697 of the 3,641 users are registered for ‘non-commercial research purposes’.
- On the basis of the data submitted to EMA, now available on the clinical data website, the Agency provides recommendations on whether a medicine should be authorised for use in the EU. The assessment reports for all these scientific opinions are available on our website.
|Unparalleled access to clinical data - one year on||(English only)||20/10/2017|
Latest News from
Opening remarks by President von der Leyen at the civil society consultation ahead of the Global Health Summit21/04/2021 12:38:00
Opening remarks given yesterday by President von der Leyen at the civil society consultation ahead of the Global Health Summit.
Road safety: 4,000 fewer people lost their lives on EU roads in 2020 as death rate falls to all-time low21/04/2021 11:33:00
The European Commission yesterday published preliminary figures on road fatalities for 2020. An estimated 18,800 people were killed in a road crash last year, an unprecedented annual fall of 17% on 2019.
The European Commission and Austria secure COVID-19 vaccines for the Western Balkans21/04/2021 10:38:00
The European Commission and Austria yesterday announced the conclusion of agreements for the delivery of COVID-19 vaccines for the Western Balkans.
New Commission Knowledge Centre on Earth Observation to further strengthen evidence-based policymaking21/04/2021 09:25:00
The Commission has launched a Knowledge Centre on Earth Observation, to maximise the use of knowledge generated from Earth Observation, in particular from the European Copernicus Programme, in EU policymaking.
EU launches €100 million humanitarian initiative to support COVID-19 vaccination campaigns in Africa20/04/2021 16:38:00
Today, Commissioner for Crisis Management, Janez Lenarčič, will visit the Africa Centres for Disease control and Prevention (Africa CDC) in Addis Ababa.
Justice, rights and values: Council adopts programmes of up to €1.8 billion for 2021-202720/04/2021 15:25:00
The Council yesterday adopted the two programmes which constitute the EU justice, rights and values fund as part of the EU financial framework for 2021-2027.
State aid: Commission adopts revised Regional Aid Guidelines20/04/2021 14:33:00
The European Commission has adopted revised EU guidelines on regional State aid (the “Regional Aid Guidelines”), setting out the rules under which Member States can grant State aid to companies to support the economic development of disadvantaged areas in the EU, while ensuring a level playing field between Member States.
Council adopts position on €14.8 billion EU space programme for 2021-202720/04/2021 13:25:00
The Council yesterday adopted its first reading position on the proposed regulation establishing the EU space programme (“the programme”) for the years 2021 to 2027.
Conference on the Future of Europe: launch of the multilingual digital platform20/04/2021 11:25:00
The Executive Board of the Conference on the Future of Europe, comprising representatives from the European Parliament, the Council of the European Union and the European Commission, is launching the multilingual digital platform for the Conference on the Future of Europe inviting all EU citizens to contribute to shaping their own future and that of Europe as a whole.